# Zepbound Psoriasis: What the Taltz + Zepbound Trials Show

Source: https://www.dietglp.com/blog/zepbound-psoriasis/
Published: 2026-10-25
Keywords: zepbound psoriasis, zepbound for psoriasis, does zepbound help with psoriasis, zepbound psoriatic arthritis, taltz and zepbound, taltz and zepbound together, taltz and zepbound savings, taltz and zepbound program, taltz and zepbound study, is zepbound approved for psoriasis, can zepbound make psoriasis worse, lilly zepbound psoriasis, glp 1 psoriasis, glp-1 for psoriasis

**TL;DR:** Zepbound (tirzepatide) is not FDA approved for psoriasis, but Lilly's TOGETHER-PsO trial, published in JAMA Dermatology, found that adding Zepbound to Taltz (ixekizumab) helped more people get fully clear skin: 40.6% vs 29.0% on Taltz alone at 36 weeks. A sister trial in psoriatic arthritis showed a similar boost. Both drugs are prescribed for their own approved uses, and Lilly runs a Zepbound savings card for Taltz patients through 2026. If you are losing weight on Zepbound, [Sharpy](${APP_LINK}) helps you keep the weight you lose coming from fat, not muscle.

Does Zepbound help with psoriasis? **On its own, Zepbound (tirzepatide) is not approved or proven as a psoriasis treatment. But when Eli Lilly added it to Taltz (ixekizumab), more people got completely clear skin.** In the TOGETHER-PsO trial, published in JAMA Dermatology in July 2026, 40.6% of people on both drugs reached 100% skin clearance at 36 weeks, compared with 29.0% on Taltz alone. Everyone in the trial had psoriasis plus obesity or overweight.

The topic is back in the news. On October 25, 2026, Medical Economics led its morning update with the Lilly combo's boost to skin clearance and weight loss in psoriasis. On October 9, Lilly shared new data at the Fall Clinical Dermatology Conference showing deeper changes in inflammation markers with the combination, as early as week 12. Here is what the research shows, in plain English.

## Why psoriasis and weight are linked

Psoriasis is an immune disease. It speeds up skin cell growth and causes thick, scaly plaques. Body fat, especially belly fat, sends out inflammatory signals too. The JAMA Dermatology authors note that overweight and obesity affect 60% to 78% of people with psoriasis, and extra weight is tied to more severe disease and weaker response to treatment.

That is the idea behind the TOGETHER trials: treat the immune side with Taltz and the weight side with Zepbound at the same time.

## TOGETHER-PsO: the Taltz and Zepbound psoriasis study

TOGETHER-PsO (NCT06588283) was a 52-week Phase 3b trial at 72 US sites. It enrolled 274 adults with moderate to severe plaque psoriasis and obesity, or overweight with at least one weight-related condition. Half got Taltz alone. Half got Taltz plus Zepbound. Both groups got diet and exercise advice.

These were not easy cases. The average BMI was 39.2, people had lived with psoriasis for about 15 years, and the average PASI score (a 0 to 72 measure of how bad psoriasis is) was 19.7.

| Result at week 36 | Taltz + Zepbound | Taltz alone |
|---|---|---|
| Fully clear skin (PASI 100) **and** 10%+ weight loss (main goal) | 27.1% | 5.8% |
| Fully clear skin (PASI 100) | 40.6% | 29.0% |
| 75% clearer skin (PASI 75) **and** 5%+ weight loss | 79.9% | 17.9% |
| Lost 10% or more of body weight | 69.2% | 9.1% |

Source: Lebwohl et al., JAMA Dermatology, July 2026.

The weight results are no surprise. The skin result is the news: Zepbound seemed to make Taltz work better. Lilly called it a 40% relative increase in complete clearance.

Two cautions. First, the trial was open label, so patients and doctors knew who got Zepbound, although the skin scores were done by blinded assessors. Second, the gap in full clearance was real but modest: the statistical range ran from 0.3 to 22.9 percentage points. A JAMA Dermatology editorial noted that we do not yet know how much came from weight loss, from tirzepatide's own anti-inflammatory effect, or from Taltz levels changing as people lost weight.

## What the new October data adds

At the Fall Clinical Dermatology Conference on October 9, 2026, Lilly shared exploratory results from the same trial. People on the combination changed 482 blood proteins vs 140 on Taltz alone, and 467 genes vs 16. The combination cut immune activity linked to neutrophils, a type of white blood cell, and some of those markers explained part of the extra skin clearing. Lilly said the gains held or improved through week 52, but it did not release week 52 numbers.

## Zepbound and psoriatic arthritis: TOGETHER-PsA

A sister trial, TOGETHER-PsA (NCT06588296), tested the same pairing in 271 adults with active psoriatic arthritis and overweight or obesity. Results were published in Arthritis and Rheumatology.

| Result at week 36 | Taltz + Zepbound | Taltz alone |
|---|---|---|
| ACR50 **and** 10%+ weight loss (main goal) | 31.7% | 0.8% |
| ACR50 (50% better joint scores) | 33.5% | 20.4% |

The joint benefit started to show as early as week 4, before people had lost much weight. That hints that tirzepatide may calm inflammation in ways beyond weight loss, but it does not prove it.

## Is Zepbound approved for psoriasis?

No. Here is how the two drugs are labeled today:

| | Taltz (ixekizumab) | Zepbound (tirzepatide) |
|---|---|---|
| What it is | IL-17A blocking antibody | GIP and GLP-1 receptor agonist |
| Approved for | Plaque psoriasis (age 6+), psoriatic arthritis, ankylosing spondylitis, nr-axSpA | Weight management in adults with obesity or overweight plus a weight-related condition; obstructive sleep apnea with obesity |
| How it is given | Injection under the skin | Weekly injection, pen or vial |
| Psoriasis approval | Yes | No |

So in real life, a doctor prescribes each drug for its own approved use: Taltz for your psoriasis, Zepbound for your weight. Lilly says it will discuss the combination data with regulators, but it has not announced a filing. For how Zepbound coverage works, see our [GLP-1 cost and coverage guide](/blog/glp1-cost-and-coverage/).

## Is it safe to take Taltz and Zepbound together?

In both trials, side effects matched what each drug already shows on its own, with no new safety concerns. In TOGETHER-PsO, the most common side effects on the combination were nausea, diarrhea, constipation, injection site reactions, dosing errors, vomiting and dizziness. Stomach side effects were more common with the combination than with Taltz alone.

A 2026 case report in JAAD Case Reports described one person whose psoriasis flared after starting tirzepatide while in remission. One case cannot show that the drug caused it, but it is a reason to tell your dermatologist about any change in your skin. Never start, stop or change either drug without talking to your prescribers.

## What about other GLP-1 drugs and psoriasis?

A 2026 review in Clinics in Dermatology found that smaller studies of liraglutide, semaglutide, exenatide, dulaglutide and tirzepatide generally showed better psoriasis scores, but most were small and uncontrolled. In a 2026 Italian real-world study of 64 adults already on Taltz, adding low-dose tirzepatide for 24 weeks cut weight by about 10% and PASI from 4.2 to about 1.0. TOGETHER-PsO is still the only large randomized trial.

## Taltz and Zepbound savings program

Lilly runs a card called **Zepbound Savings for Taltz Patients**. According to the Taltz savings page, checked October 25, 2026:

- Eligible patients could pay as little as **$25 a month** for the Zepbound single-dose pen.
- You need commercial insurance that covers **Taltz**. Your plan does not have to cover Zepbound.
- Only the Zepbound pen counts, not vials.
- Fill Taltz first. After the first Zepbound fill, Lilly checks for a recent Taltz fill (within 45 days for a 28-day Taltz supply).
- Medicare, Medicaid, VA, TRICARE and other government plans are excluded.
- The card expires **December 31, 2026**.

Questions go to Lilly at 1-833-366-7157. If you do not qualify, our [LillyDirect Zepbound guide](/blog/lillydirect-zepbound/) covers self-pay prices.

## Protect your muscle while the scale drops

Losing 10% of your body weight helps psoriasis and joints, but some of that loss can be muscle. Muscle matters even more with psoriatic arthritis, because strong muscles support sore joints. Two habits help most: eat enough protein every day (see our [protein target guide](/blog/protein-target-on-glp1/)) and lift something two or three times a week (our [resistance training guide](/blog/resistance-training-on-glp1/) has a simple plan).

[Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) puts both in one place. It gives you one daily protein target, one 20-minute strength workout you can adjust for stiff joints, and a Shape Score that shows if you are losing fat and keeping muscle.

## The bottom line

Zepbound is not a psoriasis drug, and you should not expect it to clear your skin alone. But in people with psoriasis and extra weight, adding it to Taltz helped more people reach fully clear skin and helped arthritis scores too. If both conditions apply to you, ask your dermatologist and prescriber whether the combination makes sense, and ask about Lilly's Taltz savings program. While you are on Zepbound, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) can help make sure the weight you lose is fat and not muscle. Living with sleep apnea too? See our [Zepbound sleep apnea guide](/blog/zepbound-sleep-apnea/).

## Sources

- [Lebwohl et al. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity. JAMA Dermatology, July 2026 (PubMed)](https://pubmed.ncbi.nlm.nih.gov/42139049/)
- [Merola et al. Ixekizumab With Tirzepatide in Psoriatic Arthritis and Overweight or Obesity. Arthritis and Rheumatology, Oct 2026 (PubMed)](https://pubmed.ncbi.nlm.nih.gov/41903163/)
- [Eli Lilly: TOGETHER-PsO topline results (Feb 18, 2026)](https://www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-delivered-superior-efficacy-in-first-of-its-kind-phase-3b-trial-for-adults-with-psoriasis-and-obesity-or-overweight-302691124.html)
- [Eli Lilly: New Phase 3b data on Taltz and Zepbound (Oct 9, 2026)](https://www.prnewswire.com/news-releases/new-phase-3b-data-on-lillys-taltz-ixekizumab-and-zepbound-tirzepatide-advance-understanding-of-the-interconnected-immune-and-metabolic-biology-in-adults-with-psoriasis-and-obesity-302903148.html)
- [Dermatology Times: TOGETHER-PsA topline results (Jan 8, 2026)](https://www.dermatologytimes.com/view/eli-lilly-trial-shows-superior-outcomes-with-ixekizumab-and-tirzepatide-in-patients-with-psa-and-obesity)
- [Lilly: Taltz savings and support, Zepbound Savings for Taltz Patients](https://taltz.lilly.com/savings-support)
- [Cutrona et al. GLP-1 receptor agonists in psoriasis management. Clinics in Dermatology, 2026 (PubMed)](https://pubmed.ncbi.nlm.nih.gov/42822650/)
- [Gisondi and Girolomoni. Tirzepatide in patients with psoriasis and obesity: 24-week real-world study. Dermatology and Therapy, 2026 (PubMed)](https://pubmed.ncbi.nlm.nih.gov/42240733/)
- [Psoriasis flare following tirzepatide initiation: a case report. JAAD Case Reports, 2026 (PubMed)](https://pubmed.ncbi.nlm.nih.gov/42005509/)


## Frequently asked questions

**Q: Does Zepbound help with psoriasis?**

A: In the TOGETHER-PsO trial, it helped when added to Taltz. At 36 weeks, 40.6% of people on Taltz plus Zepbound had completely clear skin (PASI 100) vs 29.0% on Taltz alone. Everyone in the trial had psoriasis plus obesity or overweight. There is no large trial of Zepbound alone as a psoriasis treatment.

**Q: Is Zepbound approved for psoriasis?**

A: No. Zepbound is FDA approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. Taltz is the drug approved for plaque psoriasis. Lilly says it will discuss the combination results with regulators.

**Q: Can you take Taltz and Zepbound together?**

A: Yes, doctors can prescribe both, each for its own approved use. In both TOGETHER trials, the two drugs were used together at US-approved doses and no new safety concerns were found. Stomach side effects such as nausea and diarrhea were more common with the combination. Your dermatologist and prescriber should decide together.

**Q: Does Zepbound help psoriatic arthritis?**

A: In the TOGETHER-PsA trial of 271 adults, 33.5% on Taltz plus Zepbound reached ACR50 (a 50% improvement in arthritis scores) vs 20.4% on Taltz alone at 36 weeks. The paper in Arthritis and Rheumatology reported that the gap started as early as week 4, before much weight was lost.

**Q: Can Zepbound make psoriasis worse?**

A: Psoriasis flares are not listed as a side effect in the Zepbound label. One 2026 case report described a flare after a patient in remission started tirzepatide, but a single case cannot show cause. If your skin gets worse after starting any new drug, tell your dermatologist.

**Q: Is there a Taltz and Zepbound savings program?**

A: Yes. Lilly's "Zepbound Savings for Taltz Patients" card says eligible patients with commercial insurance that covers Taltz could pay as little as $25 a month for the Zepbound single-dose pen, even if their plan does not cover Zepbound. Taltz must be filled first, vials are not included, government insurance is excluded, and the card ends December 31, 2026.